GlassScriptPhysician profile
Mark Richard Fox
NPI 1831147560
$2,658.54
in general payments reported to CMS, 2019-2025
27 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $748 · 2020: $206 · 2022: $364 · 2023: $451 · 2024: $611 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,340.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $290.37 | 2019-2025 | Wegovy |
| Lilly USA, LLC | $284.91 | 2019-2024 | Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $252.87 | 2020-2024 | Opdivo, Reblozyl, Eliquis |
| Alexion Pharmaceuticals, INC. | $227.58 | 2024 | Ultomiris |
| Janssen Pharmaceuticals, INC | $208.01 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.00 | 2022-2024 | Jardiance |
| Dexcom, INC. | $133.32 | 2023-2024 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $130.78 | 2019-2023 | Farxiga |
| Axsome Therapeutics, INC. | $125.00 | 2025 | Symbravo |
| Pacira Therapeutics, INC. | $124.21 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $103.15 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $97.60 | 2019 | |
| Amgen INC. | $79.43 | 2019-2024 | Prolia, Evenity, Repatha |
| Abbvie INC. | $62.42 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $51.07 | 2024 | Voquezna |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $42.39 | 2024 | Nuplazid |
| Medtronic USA, INC. | $40.53 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $37.50 | 2019 | |
| Glaxosmithkline, LLC. | $35.75 | 2024-2025 | Arexvy, Trelegy Ellipta |
| Lexicon Pharmaceuticals, INC. | $35.00 | 2023 | Inpefa |
| Xeris Pharmaceuticals, INC. | $21.75 | 2022 | |
| Amarin Pharma, INC. | $19.42 | 2019 | |
| Merck Sharp & Dohme LLC | $17.33 | 2023 | Dificid |
| Shield Therapeutics INC | $15.96 | 2023 | Accrufer |
| Daiichi Sankyo INC. | $15.79 | 2020 | |
| Mannkind Corporation | $15.71 | 2019 | |
| Pfizer INC. | $12.69 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.